Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer's Disease Treatment from Humanetics

Published: Jul 13, 2009

VIENNA, Austria & MINNEAPOLIS--(BUSINESS WIRE)--The results of a preliminary clinical trial suggest that a new Alzheimer’s drug from Humanetics Corporation is safe for daily use and that cognitive performance in patients with mild to moderate disease remained stable during the six-week course of the trial. The lack of decline in cognitive performance was an encouraging finding to be further evaluated in a Phase IIB clinical trial.

Back to news